Detalles de la búsqueda
1.
Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS.
Mult Scler
; 28(12): 1927-1936, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35672926
2.
Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials.
Eur J Neurol
; 29(4): 1238-1242, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33724637
3.
Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study.
Mult Scler
; 24(7): 963-973, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28554238
4.
Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.
J Neurol
; 271(2): 642-657, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37906326
5.
Patient-reported outcome parameters and disability worsening in progressive multiple sclerosis.
Mult Scler Relat Disord
; 81: 105139, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38000130
6.
Estimating drug concentration-response relationships by applying causal inference methods for continuous point exposures and time-to-event outcomes.
Stat Methods Med Res
; 32(12): 2440-2454, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37964549
7.
Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.
Neurol Neuroimmunol Neuroinflamm
; 10(2)2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36792367
8.
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.
EBioMedicine
; 93: 104662, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37354600
9.
Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial.
Lancet Rheumatol
; 5(2): e67-e76, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36923454
10.
Statistical analysis of PML incidences of natalizumab-treated patients from 2009 to 2016: outcomes after introduction of the Stratify JCV® DxSelect™ antibody assay.
J Neurovirol
; 22(6): 880-881, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27730447
11.
COVID-19 in ocrelizumab-treated people with multiple sclerosis.
Mult Scler Relat Disord
; 49: 102725, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33482590
12.
Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis.
Neurology
; 97(16): e1546-e1559, 2021 10 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-34475123
13.
Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: A longitudinal, retrospective study.
Mult Scler Relat Disord
; 46: 102543, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-33296966
14.
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Lancet Neurol
; 19(12): 998-1009, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33129442
15.
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
JAMA Neurol
; 77(9): 1132-1140, 2020 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32511687
16.
Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.
Neurology
; 95(13): e1854-e1867, 2020 09 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-32690791
17.
Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.
Neurology
; 93(19): e1778-e1786, 2019 11 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31484710
18.
Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
Mult Scler Relat Disord
; 24: 11-19, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29860197
19.
Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
Lancet Neurol
; 16(11): 925-933, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28969984
20.
Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses.
Mult Scler Relat Disord
; 12: 70-78, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-28283111